BACH1 and neurodegenerative disease: Despite the therapeutic potential of the NRF2-BACH1 axis, very few BACH1 inhibitors, namely, heme, cannabidiol (CBD) and HPPE (N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide have been tested in pre-clinical settings of neurodegenerative diseases up to date.